Article Text

Download PDFPDF
Immunoscintigraphic detection of tumour necrosis factor by radiolabelled certolizumab pegol in patients with erosive hand osteoarthritis: a proof-of-concept study
  1. Ruth Wittoek1,
  2. Philippe Carron1,
  3. Bieke Lambert2,3,
  4. Paulien Meersseman1,
  5. Gust Verbruggen1,
  6. Filip Van den Bosch1,
  7. Dirk Elewaut1,4
  1. 1Department of Rheumatology, Ghent University Hospital, Ghent, Belgium
  2. 2Department of Radiology and Nuclear Medicine, Ghent University, Ghent, Belgium
  3. 3Department of Nuclear Medicine, AZ Maria Middelares, Ghent, Belgium
  4. 4VIB Inflammation Research Center, Ghent University Hospital, Ghent, Belgium
  1. Correspondence to Dr Ruth Wittoek, Department of Rheumatology, Ghent University Hospital, De Pintelaan 185, Ghent B-9000, Belgium; ruth.wittoek{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Erosive hand osteoarthritis (OA) of the interphalangeal (IP) joints is characterised by a more pronounced inflammatory burden of disease.1 Whether it is a subset of hand OA or just a radiographic phase remains a matter of debate. The pathogenesis of erosive OA is not yet understood, but articular cartilage degeneration and subchondral bone resorption are some of the major characteristics. In general, several cytokine-driven pathways such as receptor activator of nuclear factor κB, interleukin-1 and tumour necrosis factor (TNF) alpha are involved at the level of the subchondral bone-inducing dynamic morphological changes.2–4 In post hoc analyses in two recent placebo-controlled pilot studies in erosive OA, it was shown that adalimumab and etanercept were able to diminish structural progression after 1 year of treatment in a subgroup of patients who showed soft tissue swelling at baseline.5 ,6

We hypothesised …

View Full Text


  • Contributors Study design: RW, PC, BL, GV, FVdB, DE. Data collection: RW, PM, BL. Data analysis: RW. Data interpretation: RW, BL, PC, FVdB, DE. Writing of the report: RW. All authors approved the final version of the manuscript.

  • Funding This work concerns an investigator-initiated study supported by UCB Pharma.

  • Competing interests None.

  • Patient consent Obtained.

  • Ethics approval Ethics Committee of Ghent University Hospital, Belgium.

  • Provenance and peer review Not commissioned; externally peer reviewed.